Researchers at University College London have made a key discovery about how cancer spreads through the body, which could lead to drugs being developed to halt the process.
Scientists at the university carried out experiments on frog and zebrafish embryos and discovered a mechanism called ‘chase and run’ that showed how diseased and healthy cells follow each other around the body, reports The Telegraph.
A new therapeutic approach can take advantage of cancer cells’ need to repair double-strand breaks in DNA, in order to overcome the tumour’s resistance to chemotherapy (Science Transl. Medicine). According to the research group headed by Hans Christian from University Cologne, mutations in the ATM gene protect cancer cells from cell death during chemotherapy. ATM is instrumental in initiating DNA repair and inducing cell death when repair is not possible in curse of the so-called DNA damage response (DDR). http://www.eurobiotechnews.eu/news/news/2013-02/double-strike-against-cancer.html
| ThromboGenics’ Jetrea receives NICE approval for eye condition treatment |
| Biopharmaceutical company ThromboGenics’ Jetrea has received approval from UK’s National Institute for Health and Care Excellence (NICE) in the treatment of some adults with vitreomacular traction (VMT), a rare eye condition… |
Ocriplasmin (trade name Jetrea) is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from theretina.[1]
Researchers at the Scripps Research Institute advance heteorcylic chemistry trhough new reagents and reaction-tracking techniques.
| http://www.pharmtech.com/pharmtech/Ingredients+Insider/Elucidating-Heterocyclic-Chemistry-in-Pharmaceutic/ArticleStandard/Article/detail/814894?contextCategoryId=43497 |
jun 2, 2013
Pharmaceutical Technology
 Patricia Van Arnum |
Heterocyclic compounds play an important role in medicinal chemistry and drug synthesis. Like any important functional class of compounds, developments that facilitate their production or elucidate their reaction mechanisms are significant for process chemists in the pharmaceutical industry. In two separate developments, researchers at The Scripps Research Institute (TSRI) in La Jolla, California recently reported on the use of zinc sulfinates as reagents for the direct chemical functionalization of nitrogen-based heterocycles and on reaction-tracking tools to better elucidate copper-catalyzed reactions in making triazoles.
Figure 1. Schematic of an antibody. Pfizer’s developmental compound tremelimumab is an antibody of subclass IgG2 and is composed of four proteins linked by disulfide bonds. Many antibodies are glycosylated, meaning that polysaccharide structures are covalently attached to the proteins at distinct sites. An antibody can have several domains that have activity, including the variable regions on the arms of the heavy and light chains, which bind to antigens, and the Fc domains, which can mediate effector functions. Adapted with permission from Pfizer, Inc.
Volume 13, Issues 13–14, July 2008, Pages 613–618
solithromycin
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-[4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl]-4-ethyl-7-fluorooctahydro-11-methoxy-3a,7,9,11,13,15-hexamethyl-10-{[3,4,6-trideoxy-3-(dimethylamino)-β-D–xylo-hexopyranosyl]oxy}-2H-Oxacyclotetradecino[4,3-d]oxazole-2,6,8,14(1H,7H,9H)-tetrone
| Legal status | Phase III clinical trials, North America, South America, Europe |
|---|---|
| Routes | oral, intravenous |
| Identifiers | |
| CAS number | 760981-83-7 |
Cempra Provides Guidance on the Clinical Program Required for Regulatory …
The Herald | HeraldOnline.com
The Phase 3 solithromycin clinical program in CABP will be planned to consist of an oral trial and an intravenous (IV)-to-oral clinical trial. Cempra followed the CABP guidance that the FDA proposed in a November, 2011, meeting of the Anti-Infective …
READ ALL AT
http://www.heraldonline.com/2013/06/13/4944834/cempra-provides-guidance-on-the.html
Solithromycin (formerly known as CEM-101 and OP-1068) is a novel ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.It is expected to be the first macrolide antibiotic available in intravenous, oral, and pediatric suspension formulations in over 20 years.
Solithromycin exhibits excellent in vitro activity against a broad spectrum of Gram-positive respiratory tract pathogens, including macrolide-resistant strains. Solithromycin has activity against a wide variety of pathogens, and further research is being conducted for other infections.
Tumor Immunotherapy Efficacy Increased In Both Breast And Prostate Cancer …
Daily Markets
NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ — Galectin Therapeutics (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that preclinical studies have shown that … The …
Aphios, VivaCell to Develop Cannabinoid-Based Drugs for MS, CNS Disorders
Genetic Engineering News
Aphios and VivaCell have executed research and commercialization agreements to develop these drug candidates through preclinical studies, clinical development, and commercialization in the U.S. and Europe. Researchers at the University of Córdoba and …
Emory University launches drug commercialization venture
DRIVE will provide the financial, business, project management and regulatory expertise to effectively move drugs through pre-clinical testing – a stage of drug development often termed the “Valley of Death” — and into proof-of-concept clinical trials.
read all at
